Claire Dimbleby

Safety and efficacy of neoadjuvant chemotherapy (NAC) in older patients with locally advanced colon cancer (LACC): Results from FOxTROT 1 and the FOxTROT 2 safety cohort population.

Janet Shirley Graham, Laura Magill, Kelly Handley, Anna Perry et autres

3653 Background: The FOxTROT1 (FT1; NCT00647530) trial demonstrated feasibility and efficacy of six weeks of NAC for LACC compared with upfront surgery. The currently recruiting FOxTROT2 trial (ISRCTN83842641) is testing this approach in older or frail patients. Outcomes in older patients with …

gb (code pays fourni par la source)

A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442).

Christopher J.M. Williams, Jake Emmerson, Andrew D. Beggs, Nicholas P. West et autres

TPS3633 Background: Meta-analysis of 6 RCTs indicates that anti-EGFR agents are ineffective in rPTL RAS-wt aCRC (Arnold D, et al. Ann Oncol. 2017;28:1713-1729). However, data from the phase III PICCOLO and COIN trials suggest high tumor expression of the EGFR ligands, EREG …

gb (code pays fourni par la source)

Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians

Małgorzata Krajnik, Nilay Hepgul, Andrew Wilcock, Ewa Jassem et autres

Abstract Background Respiratory medicine (RM) and palliative care (PC) physicians’ management of chronic breathlessness in advanced chronic obstructive pulmonary disease (COPD), fibrotic interstitial lung disease (fILD) and lung cancer (LC), and the influence of practice guidelines was explored via an online survey. …

pl, gb, it, de (code pays fourni par la source)

Can extra tests on cancer samples identify more patients with bowel/colon cancer who should be treated with drugs called anti-EGFR agents?

Claire Dimbleby, David A. Cairns

A trial assessing preoperative chemotherapy in patients with locally advanced but operable colon cancer

Claire Dimbleby

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia

Dena Howard, Anna Hockaday, Julia Brown, Walter M. Gregory et autres

BACKGROUND: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its assessment, greatly reducing the time to reach the primary outcome compared to …

gb (code pays fourni par la source)

BETTER-B: Better treatments for persistent breathlessness

Claire Dimbleby

Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuria

Claire Dimbleby

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Laura Collett, Dena Howard, Talha Munir, Lucy McParland et autres

BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and …

gb (code pays fourni par la source)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Jamie B. Oughton, Laura Collett, Dena Howard, Anna Hockaday et autres

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. METHODS/DESIGN: GA101 …

gb (code pays fourni par la source)

Additional file 1: of Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Laura Collett, Dena Howard, Talha Munir, Lucy McParland et autres

SPIRIT Checklist. (DOCX 48 kb)

Additional file 2: of Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Laura Collett, Dena Howard, Talha Munir, Lucy McParland et autres

List of centres. (DOCX 18 kb)